Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.

Kirsi NorrbackaAntoni Sicras-MainarJeremie LebrecEsther ArtimeSilvia DíazSantiago Tofé-PovedanoIgnacio HernándezIrene Romera

Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2021)

Results suggest that patients who started treatment with dulaglutide had higher persistence over 18 months, presented lower HbA1c levels at 12 months and incurred lower annual total healthcare costs than patients who initiated exenatide-QW or liraglutide.

Keyphrases

healthcare
big data
machine learning
combination therapy
replacement therapy
health information